110 related articles for article (PubMed ID: 12416033)
1. Enhancement of the antitumor effect of cyclophosphamide with the hypoxia-selective cytotoxin NLCQ-1 against murine tumors and human xenografts.
Papadopoulou MV; Ji M; Bloomer WD; Hollingshead MG
J Exp Ther Oncol; 2002; 2(5):298-305. PubMed ID: 12416033
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice.
Papadopoulou MV; Ji M; Ji X; Bloomer WD; Hollingshead MG
Cancer Chemother Pharmacol; 2002 Dec; 50(6):501-8. PubMed ID: 12451478
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic advantage from combining 5-fluorouracil with the hypoxia-selective cytotoxin NLCQ-1 in vivo; comparison with tirapazamine.
Papadopoulou MV; Ji M; Ji X; Bloomer WD
Cancer Chemother Pharmacol; 2002 Oct; 50(4):291-8. PubMed ID: 12357303
[TBL] [Abstract][Full Text] [Related]
4. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: comparison with tirapazamine.
Papadopoulou MV; Ji M; Rao MK; Bloomer WD
Oncol Res; 2001; 12(8):325-33. PubMed ID: 11589303
[TBL] [Abstract][Full Text] [Related]
5. Synergistic enhancement of the antitumor effect of taxol by the bioreductive compound NLCQ-1, in vivo: comparison with tirapazamine.
Papadopoulou MV; Ji M; Bloomer WD
Oncol Res; 2002; 13(1):47-54. PubMed ID: 12201674
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-dependent retinal toxicity of NLCQ-1 (NSC 709257) in BALB/c mice. Comparison with tirapazamine.
Papadopoulou MV; Ji M; Bloomer WD
Basic Clin Pharmacol Toxicol; 2011 Jun; 108(6):396-9. PubMed ID: 21205223
[TBL] [Abstract][Full Text] [Related]
7. NLCQ-1, a novel hypoxic cytotoxin: potentiation of melphalan, cisDDP and cyclophosphamide in vivo.
Papadopoulou MV; Ji M; Bloomer WD
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):775-9. PubMed ID: 9845094
[TBL] [Abstract][Full Text] [Related]
8. Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice.
Papadopoulou MV; Ji M; Bloomer WD
Cancer Chemother Pharmacol; 2001 Aug; 48(2):160-8. PubMed ID: 11561782
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of alkylating agents by NLCQ-1 or TPZ in vitro and in vivo.
Papadopoulou MV; Ji X; Bloomer WD
J Exp Ther Oncol; 2006; 5(4):261-72. PubMed ID: 17024967
[TBL] [Abstract][Full Text] [Related]
10. Investigational new drug-directed, 5-day repeat dose toxicity study of 4-[3-(2-nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1, NSC 709257) administered with or without Taxol in Sprague-Dawley rats.
Papadopoulou MV; Bloomer WD; Torti VR; Page JG
Basic Clin Pharmacol Toxicol; 2010 Jun; 106(6):497-504. PubMed ID: 20074267
[TBL] [Abstract][Full Text] [Related]
11. Synergistic interaction between cyclophosphamide or paclitaxel and the bioreductive compound NLCPQ-1, in vivo.
Papadopoulou MV; Ji M; Bloomer WD
Oncol Res; 2003; 13(12):561-6. PubMed ID: 12899246
[TBL] [Abstract][Full Text] [Related]
12. NLCQ-1 (NSC 709257) in combination with radiation against human glioma U251 xenografts.
Papadopoulou MV; Bloomer WD; Hollingshead MG
Anticancer Res; 2005; 25(3B):1865-9. PubMed ID: 16158918
[TBL] [Abstract][Full Text] [Related]
13. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound as a hypoxia-selective cytotoxin.
Papadopoulou MV; Ji M; Rao MK; Bloomer WD
Oncol Res; 2000; 12(4):185-92. PubMed ID: 11341468
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms involved in the potentiation of paclitaxel or 5-fU by the hypoxic cytotoxin NLCQ-1 (NSC 709257) in vitro.
Papadopoulou MV; Ji X; Bloomer WD
Anticancer Res; 2005; 25(3B):2161-70. PubMed ID: 16158959
[TBL] [Abstract][Full Text] [Related]
15. The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy.
Lunt SJ; Cawthorne C; Ali M; Telfer BA; Babur M; Smigova A; Julyan PJ; Price PM; Stratford IJ; Bloomer WD; Papadopoulou MV; Williams KJ
Br J Cancer; 2010 Jul; 103(2):201-8. PubMed ID: 20588272
[TBL] [Abstract][Full Text] [Related]
16. NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drug.
Papadopoulou MV; Bloomer WD
Clin Cancer Res; 2003 Nov; 9(15):5714-20. PubMed ID: 14654556
[TBL] [Abstract][Full Text] [Related]
17. Investigational new drug-directed toxicology and pharmacokinetic study of 4-[3-(2-nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1, NSC 709257) in Beagle dogs.
Papadopoulou MV; Bloomer WD; Torti VR; Page JG
Basic Clin Pharmacol Toxicol; 2010 Jun; 106(6):511-22. PubMed ID: 20074266
[TBL] [Abstract][Full Text] [Related]
18. Advantage of combining NLCQ-1 (NSC 709257) with radiation in treatment of human head and neck xenografts.
Papadopoulou MV; Bloomer WD; Taylor AP; Hernandez M; Blumenthal RD; Hollingshead MG
Radiat Res; 2007 Jul; 168(1):65-71. PubMed ID: 17722994
[TBL] [Abstract][Full Text] [Related]
19. DNA repair mechanisms are involved in the hypoxia-dependent toxicity of NLCQ-1 (NSC 709257) and its synergistic interaction with alkylating agents.
Papadopoulou MV; Bloomer WD
In Vivo; 2007; 21(2):175-80. PubMed ID: 17436565
[TBL] [Abstract][Full Text] [Related]
20. Synergistic interaction between tirapazamine and cyclophosphamide in human breast cancer xenografts.
Langmuir VK; Rooker JA; Osen M; Mendonca HL; Laderoute KR
Cancer Res; 1994 Jun; 54(11):2845-7. PubMed ID: 8187065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
